Predicting survival of de novo metastatic breast cancer in Asian women: Systematic review and validation study by Miao, H. et al.
Predicting Survival of De Novo Metastatic Breast Cancer
in Asian Women: Systematic Review and Validation
Study
Hui Miao1, Mikael Hartman1,2,3*, Nirmala Bhoo-Pathy4,5, Soo-Chin Lee6, Nur Aishah Taib7, Ern-Yu Tan8,
Patrick Chan8, Karel G. M. Moons5, Hoong-Seam Wong4, Jeremy Goh9, Siti Mastura Rahim10,
Cheng-Har Yip7, Helena M. Verkooijen1,11
1 Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore, 2Department of Surgery, Yong
Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore, 3Department of Medical Epidemiology and
Biostatistics, Karolinska Institutet, Stockholm, Sweden, 4National Clinical Research Centre, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, 5 Julius Center for Health
Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands, 6Department of Hematology Oncology, National University Cancer Institute, National
University Health System, Singapore, Singapore, 7Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 8Department of Surgery,
Tan Tock Seng Hospital, Singapore, Singapore, 9 Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore,
Singapore, 10Ministry of Health Holdings, Singapore, Singapore, 11Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands
Abstract
Background: In Asia, up to 25% of breast cancer patients present with distant metastases at diagnosis. Given the
heterogeneous survival probabilities of de novo metastatic breast cancer, individual outcome prediction is challenging. The
aim of the study is to identify existing prognostic models for patients with de novo metastatic breast cancer and validate
them in Asia.
Materials and Methods: We performed a systematic review to identify prediction models for metastatic breast cancer.
Models were validated in 642 women with de novo metastatic breast cancer registered between 2000 and 2010 in the
Singapore Malaysia Hospital Based Breast Cancer Registry. Survival curves for low, intermediate and high-risk groups
according to each prognostic score were compared by log-rank test and discrimination of the models was assessed by
concordance statistic (C-statistic).
Results: We identified 16 prediction models, seven of which were for patients with brain metastases only. Performance
status, estrogen receptor status, metastatic site(s) and disease-free interval were the most common predictors. We were
able to validate nine prediction models. The capacity of the models to discriminate between poor and good survivors varied
from poor to fair with C-statistics ranging from 0.50 (95% CI, 0.48–0.53) to 0.63 (95% CI, 0.60–0.66).
Conclusion: The discriminatory performance of existing prediction models for de novo metastatic breast cancer in Asia is
modest. Development of an Asian-specific prediction model is needed to improve prognostication and guide decision
making.
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Introduction
Global incidence rates of breast cancer are on the rise and the
increase is largely due to an upsurge in breast cancer rates in Asia
[1]. Asian women are more likely to be diagnosed with late stage
disease compared to their Western counterparts. Approximately
10% to 25% of Asian breast cancer patients present with de novo
metastatic disease, compared to 3% to 5% in Europe and United
States [2,3,4,5,6]. In addition, metastatic lesions in Asian women
are larger and often involve multiple sites [7].
Metastatic breast cancer is incurable. Median survival rates
range from one to four years, but on an individual level, survival
times of up to 15 years have been reported
[8,9,10,11,12,13,14,15]. While recent studies suggest that surgical
removal of primary breast tumor has a positive impact on the
survival of de novo metastatic patients [16,17,18], systemic therapy,
is the main treatment. Due to advances in loco-regional and
systemic treatment and due to the detection of small, solitary
metastases, survival has improved over time, especially in patients
with hormone receptor-positive tumors [12,15].
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Accurate assessment of individual prognosis of patients with de
novo metastatic breast cancer is needed for treatment decision
making. In addition, like all patients with cancer, women with
distant metastases want to know their prognosis [19]. As clinicians
are known to be overoptimistic in predicting survival [20],
prediction rules can be useful for this heterogeneous group of
patients with different treatment options. Although many multi-
variable prognostic indices have been developed for breast cancer
in the last two decades, the majority are not applicable to patients
with de novo metastatic disease [21,22,23]. In this study, we aim to
identify prediction tools which can be used for prognostication of
patients with de novo metastatic breast cancer and externally
validate their performance in the Singapore-Malaysia hospital-
based breast cancer registry.
Materials and Methods
Ethics statement
This study obtained ethics approval from National Healthcare
Group (NHG) Domain Specific Review Board (DSRB).
Systematic review
Our first step was to perform a systematic review of the available
literature, according to the PRISMA guidelines [24]. A free text
search was performed on 13 August 2013 to identify eligible
studies using MEDLINE and EMBASE electronic database. Our
search strategy included search terms and synonyms for prognostic
models and the following string was used: ((metastatic breast
cancer) AND ((prognostic scor* OR prognostic index OR
nomogram OR predictive model OR validation OR validate
OR prognostic model OR predictor) AND (scor* OR index OR
model OR predict* OR nomogram OR validat*))) NOT
(expression profiling OR microarray* OR proteomic OR affyme-
trix). After reviewing the titles and abstracts, full text was selected
applying predefined in- and exclusion criteria. Included were
studies presenting multivariable models, with the aim to predict
overall survival of metastatic breast cancer patients. We excluded
animal models or clinical trials on treatment efficacy, as well as
studies which used disease free, progression free survival or
response to treatment as the only outcome of interest. Etiological
studies which only assessed the effect size of one specific prognostic
factor or only evaluated the prognostic value of a single biomarker
were not included. We also excluded prediction tools developed
for patients with metastases from various primary cancers.
Prognostic tools for patients with advanced cancer nearing the
end of life or tools specific for recurrent metastatic breast cancer
were not included as these patients have been exposed to multiple
chemotherapy regimens and are often treatment resistant. Two
studies which validated previously published models in metastatic
breast cancer patients were excluded. Additional articles were
retrieved by cross-referencing. Details regarding the author, year
of publication, study design, model variables and performance
measures were extracted if available. Quality of the selected
publications was assessed using items listed in the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) statement, which were relevant to our study [25].
Validation set
Validation of the performance of the selected prediction models
was performed within the Singapore Malaysia Hospital Based
Breast Cancer Registry. This registry consists of three hospital-
based breast cancer registries in Singapore and Malaysia. National
University Hospital (NUH) and Tan Tock Seng Hospital (TTSH)
are two public tertiary hospitals in Singapore. The registry at
NUH includes cases diagnosed between 1990 and 2010 while the
TTSH registry started in 2001. University Malaya Medical Centre
(UMMC), an academic tertiary hospital in Kuala Lumpur,
Malaysia, has prospectively collected breast cancer cases from
1993 to 2008. All three registries include data on basic patient
demography, clinical and pathological tumor characteristics and
treatment profile. These registries have received approval from
respective ethical review committees. Death information was
obtained from the hospitals’ medical records and ascertained by
linkage to National Registration Departments in both countries.
Patients were followed up from the date of diagnosis until the date
of death or date of last contact whichever came first. The date of
last contact was 1 November 2010 for UMMC patients, 1 July
2011 for NUH patients and 1 October 2012 for TTSH patients.
Details of the registries have been described previously [3,4,26].
Breast cancer patients with distant metastasis detected within three
months after diagnosis were identified from this registry and
formed the basis of this study. Individual data on the date of birth,
ethnicity, tumor size, grade, estrogen receptor (ER) status,
progesterone receptor (PR) status, human epidermal growth factor
receptor 2 (HER2) status, site(s) of metastasis and treatment were
available in the registry. For NUH patients we went back to the
clinical files as site(s) of metastasis was not systematically recorded.
Due to the lack of information on hormone receptor status in the
early years, we restricted our cohort to women diagnosed between
2000 and 2010. Patients with metastases in the ipsilateral
supraclavicular lymph nodes but no metastasis at any other
distant site were not considered as metastatic patients, according to
the sixth edition of the tumor node metastasis classification of the
American Joint Committee on Cancer (AJCC) [27].
Statistical analysis
In the validation set, we investigated the pattern of missing data
and assumed that data missingness was related to at least one other
variable but not dependent on value of the observation itself, i.e.
missing at random [28]. A total number of 230 (36%) individuals
had complete data on all variables used in validation and 90 (14%)
cases had 3 or more variables missing. On average, each individual
had 1.13 variables missing (standard deviation = 1.22), ranging
from 0 to 5. Missing values were imputed once using regression
imputation [28].
For each individual patient, we calculated the prognostic score
for the different prognostic models/indices except for those
developed by recursive partitioning analysis [29] and artificial
neural network [30], as terminal nodes were missing in our dataset
or algorithm was not provided to allow calculation of prognostic
scores. For models including performance status, a variable that
was not captured in our database, we assumed all patients to be fit
at the time of diagnosis, i.e. 0 on Zubrod scale, which is the same
as the Eastern Cooperative Oncology Group (ECOG) and the
WHO scale, and 100 on the Karnofsky performance status (KPS)
scale. In order to check this assumption, we retrieved comorbidity
data from the medical records of a subset of 87 NUH patients who
diagnosed after 2006. We also assumed the best case scenario for
lactate dehydrogenase (LDH). For brain metastasis models, a score
of zero (best case scenario) was assigned to the largest brain
metastasis dimension in Marko et al.’s model. We assumed no
trastuzumab use for HER2 positive patients in Ahn et al.’s model,
as in Singapore and Malaysia trastuzumab use was rare during the
time of our study. Since our study population consisted of patients
who were metastatic at presentation, disease free interval (DFI)
was set as zero for all women.
The distribution of each prognostic score was then divided into
tertiles with the exception for Rabinovich’s model, for which were
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only two possible combinations. We compared the survival of low,
intermediate and high-risk score patients by plotting the Kaplan
Meier survival curves for each tertile. Median survival and 95%
confidence intervals (CI) were obtained for different groups and
differences were tested by log-rank test and log-rank test for trend.
The discrimination ability of the models was assessed by
concordance statistic (C-statistic), which is the probability of
correctly distinguishing between deceased and surviving patients
within a random pair of patients [31]. The interpretation of C-
statistic is equivalent to area under a curve (AUC) in receiver
operating characteristic (ROC) analysis. A value of 0.5 indicates
no discrimination and value of 1.0 means perfect discrimination.
For models with C-statistic larger than 0.6, 1-year, 2-year and 3-
year cumulative survival probabilities were plotted for each
quintile of the prognostic score to test calibration.
Results
Systematic review
The search strategy resulted in 1298 titles (Figure 1). Forty-eight
full text articles were selected after screening the titles and
abstracts and two articles were added by cross-referencing. A total
of 16 prognostic indices met our inclusion criteria. Eight models
were developed for patients with metastatic breast cancer in
general, seven for patients with brain metastasis from breast cancer
and one for breast cancer patients with metastatic spinal cord
compression [32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47].
All prognostic indices were designed for both de novo and recurrent
metastatic breast cancer patients (Table 1). Study sizes ranged
from 83 to 619 patients, with a median study size of 246 patients.
The median survival from time of detection of metastasis ranged
from 9.6 to 22 months. Cox regression incorporated time-to-event
data and all-cause mortality as outcome was used for model
development in 13 studies. Three studies conducted recursive
partitioning analysis and one used artificial neural network. For
Cox regression modeling, forward or backward stepwise selection
with different cut-off P-values, either 0.05 or 0.1 was applied to
identify final predictors.
Performance status, ER status, metastatic site(s) and disease free
interval were the most common prognostic factors included in the
different models. Performance status was measured on different
scales, i.e. five studies used Zubrod/ECOG/WHO score while 6
models for brain metastasis used KPS [33,35,37,39,41,42,43,
44,45,46,47]. Model coefficients or hazard ratios were presented
in all Cox regression models. Six studies transformed the model into
a scoring system for easy calculation of predicted survival and three
studies developed a nomogram [32,36,37,39,41,42,43,44,47].
Recursive decision tree was constructed from recursive partitioning
analysis in two studies [48,49]. Only 5 studies evaluated the
discrimination of their models using C-statistic or AUC [35,38,39,
43,44], which ranged from 0.67 to 0.74 (moderate discrimination).
Figure 1. Flow chart of study selection process. n = number of studies.
doi:10.1371/journal.pone.0093755.g001
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Calibration was assessed by plotting predicted versus observed
survival for only two models, which turned out to be well calibrated
[43,44]. Four studies conducted internal validation using random
subset of data, ten-fold cross-validation and bootstrapping with 200
and 1000 resamples [38,43,44,47,49]. Temporal validation of the
model using data collected from the same hospital but later than
those in the development set was conducted in four studies
[33,35,37]. Five models were externally validated in other hospitals
or outside the original country [36,39,43,44,48]. Quality of the
selected publications is summarized in Table 2.
Validation
Our validation set included 642 Asian de novo metastatic breast
cancer patients with a median age of 53 years (range, 24–94).
Table 3. Characteristics of de novo metastatic breast cancer patients identified at NUH, TTSH and UMMC, 2000–2010.
UMMC NUH TTSH Overall
Total 266 (41.4%) 156 (24.3%) 220 (34.3%) 642
Median Survival in months (95% CI) 14.0 (11.7–16.3) 28.0 (20.9–35.1) 18.0 (12.2–23.8) 19.0 (16.5–21.5)
Median age at diagnosis in years (range) 50 (24–83) 53 (28–80) 58 (30–94) 53 (24–94)
Median tumor size in mm (range) 100 (5–300) 40 (2–210) 60 (2–200) 60 (2–300)
Ethnicity Chinese 148 (55.6%) 95 (60.9%) 152 (69.1%) 395 (61.5%)
Malay 88 (33.1%) 38 (24.4%) 39 (17.7%) 165 (25.7%)
Indian 30 (11.3%) 12 (7.7%) 15 (6.8%) 57 (8.9%)
Others 0 (0.0%) 11 (7.1%) 14 (6.4%) 25 (3.9%)
Grade 1 2 (0.8%) 5 (3.2%) 3 (1.4%) 10 (1.6%)
2 53 (19.9%) 64 (41.0%) 40 (18.2%) 157 (24.5%)
3 63 (23.7%) 70 (44.9%) 41 (18.6%) 174 (27.1%)
Unknown 148 (55.6%) 17 (10.9%) 136 (61.8%) 301 (46.9%)
ER status Negative 102 (38.3%) 51 (32.7%) 81 (36.8%) 234 (36.4%)
Positive 116 (43.6%) 103 (66.0%) 129 (58.6%) 348 (54.2%)
Unknown 48 (18.0%) 2 (1.3%) 10 (4.5%) 60 (9.3%)
PR status Negative 104 (39.1%) 62 (39.7%) 130 (59.1%) 296 (46.1%)
Positive 63 (23.7%) 92 (59.0%) 80 (36.4%) 235 (36.6%)
Unknown 99 (37.2%) 2 (1.3%) 10 (4.5%) 111 (17.3%)
HER2 status Negative 64 (24.1%) 71 (45.5%) 75 (34.1%) 210 (32.7%)
Positive 77 (28.9%) 24 (15.4%) 57 (25.9%) 158 (24.6%)
Equivocal 20 (7.5%) 12 (7.7%) 17 (7.7%) 49 (7.6%)
Unknown 105 (39.5%) 49 (31.4%) 71 (32.3%) 225 (35.0%)
Site(s) of metastases Bone only 57 (21.4%) 25 (16.0%) 46 (20.9%) 128 (19.9%)
Lung only 45 (16.9%) 11 (7.1%) 30 (13.6%) 86 (13.4%)
Liver only 22 (8.3%) 9 (5.8%) 20 (9.1%) 51 (7.9%)
Brain only 5 (1.9%) 2 (1.3%) 2 (0.9%) 9 (1.4%)
Soft tissue only 5 (1.9%) 0 (0.0%) 3 (1.4%) 8 (1.2%)
Other organ only 2 (0.8%) 1 (0.6%) 3 (1.4%) 6 (0.9%)
Multiple sites 118 (44.4%) 104 (66.7%) 106 (48.2%) 328 (51.1%)
Unknown 12 (4.5%) 4 (2.6%) 10 (4.5%) 26 (4.0%)
Surgery No surgery 155 (58.3%) 84 (53.8%) 165 (75.0%) 404 (62.9%)
Mastectomy 111 (41.7%) 63 (40.4%) 51 (23.2%) 225 (35.0%)
Breast conserving surgery 0 (0.0%) 9 (5.8%) 4 (1.8%) 13 (2.0%)
Chemotherapy No 101 (38.0%) 77 (49.4%) 53 (24.1%) 231 (36.0%)
Yes 164 (61.7%) 79 (50.6%) 94 (42.7%) 337 (52.5%)
Unknown 1 (0.4%) 0 (0.0%) 73 (33.2%) 74 (11.5%)
Radiotherapy No 115 (43.2%) 106 (67.9%) 129 (58.6%) 350 (54.5%)
Yes 96 (36.1%) 45 (28.8%) 19 (8.6%) 160 (24.9%)
Unknown 55 (20.7%) 5 (3.2%) 72 (32.7%) 132 (20.6%)
Hormone therapy No 63 (23.7%) 95 (60.9%) 120 (54.5%) 278 (43.3%)
Yes 121 (45.5%) 58 (37.2%) 29 (13.2%) 208 (32.4%)
Unknown 82 (30.8%) 3 (1.9%) 71 (32.3%) 156 (24.3%)
doi:10.1371/journal.pone.0093755.t003
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Patient characteristics are reported in Table 3. Over a follow-up
period of 1267.6 person-years, 492 patients had died and the
median survival time was 19 months (95% CI, 16.5–21.5). The 1-
year, 2-year and 3-year survival rates were 62%, 43% and 31%
respectively. Half of the patients had more than one metastatic site
involved and the majority did not receive any surgery or
radiotherapy. Chemotherapy and hormone therapy were admin-
istered to 53% and 32% of the study population respectively.
Among the 87 NUH patients with comorbidity data, hypertension
(30%) and diabetes (23%) were the most common medical
conditions. Less than 10% of this group was suffering from
coronary heart disease (7%), stroke (2%), chronic obstructive
pulmonary disease (3%) and renal failure (1%) and 6% of the
patients have more than two comorbidities.
We validated all models that used Cox regression, with the
exception of the models developed by Hortobagyi et al., Giordano
et al., Le Scodan et al. and Rades et al. because the key predictors
alkaline phosphatase (ALKP), circulating tumor cells (CTC),
lymphocyte count and metastasis to spine were not available.
Only Williams et al.’s, Yamamoto et al.’s, Rabinovich et al.’s and
Ryberg et al.’s models were able to significantly discriminate
between different risk groups in terms of overall survival based on
log-rank test (Figure 2). The median survival for the low-risk
group, intermediate-risk group and high-risk group classified
according to Williams et al.’s model was 30 months, 21 months
and 10 months respectively. For Rabinovich et al.’s model with
two possible combinations, the median survival was 27 months
and 16 months for the low and high risk groups. For Ryberg et
al.’s model, the median survival was 29, 17 and 10 months
respectively for the three groups. However the log-rank for trend
test was not significant for Yamamoto et al.’s model as the median
survival was 17 months for the low risk group, 24 months for the
medium risk group and 15 months for the high risk group.
In our cohort, discrimination of the different models was poor to
fair, with C-statistics ranging from 0.51 to 0.63 (Table 4). The
model with the highest discriminatory ability was the model
developed by Williams et al. (C-statistic 0.63, 95% CI 0.60–0.66),
followed by Ryberg et al. (C-statistic 0.61, 95% CI 0.59–0.64). A
notable decreasing trend of 1-year, 2-year and 3-year cumulative
survival probabilities was observed for the five risk groups
Figure 2. Kaplan Meier survival curves of low, intermediate and high-risk groups. Risk groups were defined by tertiles of risk scores of
prediction models for patients with de novo metastatic breast cancer.
doi:10.1371/journal.pone.0093755.g002
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Figure 3. 1-, 2- and 3-year cumulative survival probability for different risk groups. Risk groups were defined by quintiles of risk scores of
Williams et al.’s and Ryberg et al.’s model. 1st quintile is the group with the highest predicted survival probability and 5th quintile is with the lowest
predicted survival probability.
doi:10.1371/journal.pone.0093755.g003
Table 4. Validation of selected models for prediction of survival of patients with de novo metastatic breast cancer.
Model
Number of subjects available for
validation Possible range of scores Observed range of scores C-statistic (95% CI)
Nash et al. 642 0.23–3.44 0.23–3.44 0.51 (0.48,0.53)
Williams et al. 571a 22.00–32.00 1.23–32.00 0.63 (0.60,0.66)d
Rabinovich et al. 642 0.80–2.38 0.80–1.05 0.55 (0.53,0.57)
Yamamoto et al. 642 0.00–6.33 3.33–6.33 0.50 (0.48,0.53)
Ryberg et al. 642 0.00–50.00 0.00–25.00 0.61 (0.59,0.64)
Nieder et al. 52c 0.00–5.00 1.00–3.00 0.55 (0.48,0.61)
Sperduto et al. 50b,c 0.00–4.00 1.50–4.00 0.56 (0.47,0.65)
Ahn et al. 50b,c 0.00–325.00 0.00–138.00 0.56 (0.46,0.66)
Marko et al. 52c 0.00–375.00 44.50–108.60 0.55 (0.45,0.64)
aPatients with brain metastases excluded.
bPatients with equivocal Her2 status were excluded.
cExclusively patients with brain metastasis.
dC-statistic for complete case analysis based on 297 patients was 0.63 (95% CI, 0.59–0.67).
doi:10.1371/journal.pone.0093755.t004
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(quintiles, Figure 3). For Williams et al.’s model, the 3-year survival
probabilities for the lowest and highest risk group were 49% (95%
CI, 39%–58%) and 10% (95% CI, 4%–16%) respectively. For
Ryberg et al.’s model, 3-year survival probabilities were 53% (95%
CI, 45%–61) and 13% (95% CI, 7%–19%) for the low versus high
risk groups respectively.
Discussion
Survival after de novo metastatic breast cancer, a relatively
common condition among breast cancer patients in South East
Asia, varies considerably. In this study, we showed that this highly
variable prognosis can be predicted using currently available
prediction rules, only to a certain extent in Asian patients.
Overall, the prediction performance in the present series in Asia
was not as good as in the original reports. Some of these
prediction rules, which were identified through systematic review
of the literature, used easily available clinical information such as
age, hormone receptor status and site of metastasis. Some other
models included biomarkers, which are not routinely available
during the work up of breast cancer patients such as CTC and
LDH.
We validated nine of the models in our Asian dataset and
found that two models performed moderately well. In fact,
with basic clinical information, (i.e. grade, ER status and site of
metastasis), these models were able to classify patients as high
risk and low risk. Based on risk scores calculated from Williams
et al.’s and Ryberg et al.’s models, which included simple freely
available clinical information, the difference of 3-year survival
probability between the highest and lowest quintiles was close
to 40%. Still, there was substantial overlap between the
categories, and the current prediction rules were at best fairly
able to discriminate between low and high risk patients (highest
C-statistic = 0.63). Comparing to the other 3 models developed
for all metastatic breast cancer patients, the models developed
by Williams et al and Ryberg et al incorporated ER status and
also grouped metastatic site into more categorizes. We were
unable to validate the models which included advanced
biomarkers, as this information was not routinely captured in
our patients.
The inferior performance of the models in our Asian dataset as
compared to the original report could be explained by
unavailability of some predictors in our cohort and the fact that
these indices/models were not specifically designed for de novo
metastatic breast cancer. Another explanation could be that the
Western derived models are not suitable for Asia setting. For
example, in women with stage I–III breast cancer, Adjuvant!On-
line overpredicted survival by almost 7% and this overprediction
was especially pronounced in younger women and women of
Malay descent [50]. The underlying cause might be different
distributions of age, tumor characteristics, competing risks and
life styles factors. Several studies have reported that Asian breast
cancer patients are more likely to be premenopausal, ER/PR-
negative and HER2-positive [51,52,53]. Such differences could
result in more skewed or more restricted range of prediction
scores (Table 4).
Accuracy of predicting survival is crucial for women with de
novo metastatic breast cancer as treatment varies widely, from
no treatment at all, to removal of primary tumor and
aggressive systemic treatment. The use of endocrine therapy
and anti-HER2 drugs has been shown to prolong survival of
metastatic patients.[54,55,56] Many randomized control trials
have also reported significant survival benefit from modern
chemotherapeutic agents, such as taxanes [57]. Recent studies
have suggested that women who undergo surgery for de novo
metastatic breast cancer have a significantly lower risk of death
as compared to those who do not [16,17,18]. However the high
proportion of patients not treated in our cohort or different
response to treatment between Asian and Caucasian women
may affect the usefulness of certain predictors such as hormone
receptor status as well as the overall performance of the
prediction models.
We acknowledge that our study suffers from limitations. The
main limitation of the current study is the unavailability of
certain clinical variables for prediction in our database such as
performance status and LDH. Performance status, either
recorded in Zubrod/ECOG/WHO or KPS, is a significant
predictor in 11 indices/models. According to the development
studies, 60% to 79% of their study population in fact had good
performance status (Zubrod/ECOG/WHO= 0 or 1 or KPS$
70). Based on the results from a subset of patients with
comorbidity data in our validation set, our assumption of
patients to be generally fit may have resulted in some
overestimation of predicted survival probabilities for a subset
of patients. The number of CTC has been shown to be highly
predictive for overall survival in patients with metastatic breast
cancer [58,59]. The CELLSEARCH test (Veridex, LLC,
Raritan, NJ, USA) is the first and only clinically validated,
FDA-cleared system for CTC assessment [60,61]. However it
is not routinely measured in Asia and is unlikely to be
measured in future in low and middle income countries. The
underperformance of models developed for brain metastasis
maybe partially caused by the exclusion of non-treated patients
in the development study, the lack of largest brain metastasis
dimension and trastuzumab use in our validation dataset.
Another limitation of our validation is the incomplete data of
certain predictors. The pattern of missingness suggested
missing at random and thus imputation is a better and more
reasonable option than complete case analysis. The C-statistic
for Williams et al’s model from complete case analysis of 297
patients with grade, ER status and metastatic site(s) was 0.63
(95% CI, 0.59–0.67), which was very similar to the result from
imputation (0.63, 95% CI, 0.60–0.66). However the standard
errors and confidence intervals of the estimates might be too
low as we ignored the uncertainty of imputed values by single
imputation.
We conclude that existing prognostic models can only
moderately predict survival of women with de novo metastatic
breast cancer in the Asian setting. New models derived from a
representative sample from an Asian population with different
disease burden, would be able to accurately discriminate between
patients with relatively good versus poor prognosis better.
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